Brand Firm In-House Generics Unlikely To Grab Large Market Share – Analyst

Brand companies that launch their own generics are unlikely to capture significant market share but will exert pricing pressure on the ANDA first-filer, a Lehman Brothers analyst said

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet